Effect of Diazoxide on the Obesity Secondary to Hypothalamic-pituitary Lesions
Hypothalamic-pituitary Lesions, Craniopharyngiomas
About this trial
This is an interventional treatment trial for Hypothalamic-pituitary Lesions focused on measuring Hypothalamic-pituitary lesions, Craniopharyngioma, Obesity, Diazoxide, Hyperinsulinemia, Pediatric neurosurgery, Oncology, Pituitary, Hypothalamus
Eligibility Criteria
Inclusion Criteria: Age 6 to 18 years Obesity with body mass index > 97 percentile or > 2 SD Hypothalamic-pituitary lesions not evolutive Hyperinsulinemia defined by insulin peak after oral glucose tolerance test>100 UI/L Absence of diabetes mellitus defined by basal plasma glucose < 1.2 g/L and glucose peak after oral glucose tolerance test < 2 g/L and HbA1c < 7 % Hormonal replacement therapy stable from at least three months excluding the treatment of diabetes insipidus which can be adjusted Normal plasma thyroxine Written informed consent of the children and the parents Exclusion Criteria: evolutive lesion recent surgery or radiotherapy (< 6 months) modification of hormonal replacement therapy during the three previous months diabetes mellitus defined by basal plasma glucose > 1.2 g/L and glucose peak after oral glucose tolerance test > 2 g/L and HbA1c > 7 % renal or hepatic failure uncontrolled hypertension hypersensitivity to benzothiazine drugs pregnancy difficulties to understand the protocol
Sites / Locations
- Hopital Kremlin-Bicetre